Targeting PEG10 as a novel therapeutic approach to overcome CDK4/6 inhibitor resistance in breast cancer

BACKGROUND: Breast cancer is the global leading cancer burden in women and the hormone receptor-positive (HR+) subtype is a major part of breast cancer. Though cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors are highly effective therapy for HR+ subtype, acquired resistance is inevitable in most...

Descripción completa

Detalles Bibliográficos
Autores principales: Katuwal, Nar Bahadur, Kang, Min Sil, Ghosh, Mithun, Hong, Sa Deok, Jeong, Yeong Gyu, Park, Seong Min, Kim, Seul-Gi, Sohn, Joohyuk, Kim, Tae Hoen, Moon, Yong Wha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10683152/
https://www.ncbi.nlm.nih.gov/pubmed/38017459
http://dx.doi.org/10.1186/s13046-023-02903-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10683152/
https://www.ncbi.nlm.nih.gov/pubmed/38017459
http://dx.doi.org/10.1186/s13046-023-02903-x

Ejemplares similares